Prof Christian Gisselbrecht (St. Louis Hospital, Paris, France) discusses results of recent clinical studies in Hodgkin lymphoma (HL) presented at the 2014 American Society of Hematology (ASH) Annual Meeting, including brentuximab vedotin in combination with other agents, positron emission tomography (PET) for tailored treatment and PD-1 immune checkpoint inhibitors.
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content